The association between famotidine and in‐hospital mortality of patients with COVID‐19
MD Toshiki Kuno, Matsuo So, Mai Takahashi, Natalia N Egorova
Journal of Medical Virology, doi:10.1002/jmv.27375
Famotidine has been considered to be a potential treatment for COVID-19 but the current data is conflicting. This retrospective study was conducted by utilizing data of 9565 COVID-19 hospitalized patients. Patients treated with and without famotidine were matched by propensity score using a 1:1 matching scheme. A total of 1593 patients (16.7%) received famotidine. In-hospital mortality was similar in patients treated with and without famotidine in the propensity-matched cohorts (28.3% vs. 28.2%, p = 0.97), which remains similar irrespective of severity or concomitant treatment by steroids. Famotidine treatment was not associated with a lower risk of in-hospital mortality of COVID-19 patients.
CONFLICT OF INTERESTS The authors declare that there are no conflict of interests.
ETHICS STATEMENT This study was approved by the Institutional Review Boards (#2000495) and conducted in accordance with the principles of the Declaration of Helsinki. The waiver of patients' informed consent was also approved by the institutional review boards.
AUTHOR CONTRIBUTIONS Toshiki Kuno, Mai Takahashi, and Natalia N. Egorova had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Toshiki
References
Castells, Butterfield, Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management, J Allergy Clin Immunol Pract
Freedberg, Conigliaro, Wang, Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study, Gastroenterology
Kuno, Miyamoto, Iwagami, Ishimaru, Takahashi et al., The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroids, J Antimicrob Chemother
Kuno, So, Miyamoto, Iwagami, Takahashi et al., The association of COVID-19 antibody with in-hospital outcomes in COVID-19 infected patients, J Med Virol,
doi:10.1002/jmv.27260Kuno, So, Takahashi, Egorova, U shape association of hemoglobin level with in-hospital mortality for COVID-19 patients, J Thromb Thrombolysis
Malone, Tisdall, Smith, COVID-19: famotidine, histamine, mast cells, and mechanisms, Front Pharmacol
Mather, Seip, Mckay, Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19, Am J Gastroenterol
Mukherjee, Bhattacharya, Bojkova, Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection, J Biol Chem
Shoaibi, Fortin, Weinstein, Berlin, Ryan, Comparative effectiveness of famotidine in hospitalized COVID-19 patients, Am J Gastroenterol
So, Kabata, Takahashi, Egorova, Kuno, The association of inhaled corticosteroid before admission and survival of patients with COVID-19, J Aerosol Med Pulm Drug Deliv
Sterne, Murthy, Diaz, Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis, JAMA
